Cuenta del usuario Aaabbbcccddd

Aaabbbcccddd 07/03/25 10:31

Ha respondido al tema Laminar Pharmaceuticals

Por si ayuda, hay algunos cambios que se han hecho en las empresas que giran alrededor de Laminar y que podrían dar alguna idea de lo que querrá hacer la empresa en el futuro.MELITHERAPY SL (B16684409)Escriba se convierte en apoderado (Diciembre 2024)Entiendo que esta empresa es la que se utiliza para gestionar Laminar y otras empresas en la orbita (Ej; Neurofix Pharma).VERITAS THERAPEUTICS SL (B42781823)Alguna patente se ha asociado a esta compañía en lugar de Laminar.

Aaabbbcccddd 05/03/25 17:20

Ha respondido al tema Laminar Pharmaceuticals

La nota de prensa en inglés incluye lo siguiente (negrita mía):"Although the main primary outcome of the interim analysis (Hazard Ratio of 0.5 for PFS) was not reached for the whole trial population, the unblinding of the trial has allowed Laminar to conduct an ongoing evaluation (non-statistically assessed and with data under monitoring review) considering the per protocol predefined stratification: methylation status of the MGMT promoter and RTOG score (3, 4 or 5), a scale describing the side effects caused by radiation therapy and the higher the RTOG score the worse the clinical position. By revising the data stratified by MGMT promoter methylation status and RTOG, and using data available on 18th February 2025, the median PFS for methylated patients RTOG3 was 56,7 weeks on the LAM561 treatment arm against 19 weeks on the placebo arm (n=9). Moreover, the median PFS for methylated patients RTOG4 was 86,4 weeks on the LAM561 treatment arm against 54,7 weeks on the placebo arm (n=39). With currently available data, methylated patients treated with LAM561 + SoC seem to experience a potentially clinically relevantimprovement in PFS (Hazard-ratio estimation of 0.53) compared to control group (placebo+SoC). PFS was not improved by LAM561 in unmethylated patients. This interim perspective should be taken with caution since the study is still ongoing and providing new information and the final interpretation will only be apparent once the study has completed after reaching 90 OS events; and, although progression of the disease is a relevant clinical event, overall survival is the primary outcome of the trial and conclusions on the final effect of the drug need to wait until the final analysis is performed and data is reviewed by the IDMC. Laminar intends to perform an in-depth independent objective assessment of the findings."https://www.prnewswire.com/news-releases/laminar-pharma-announces-first-open-label-progression-free-survival-data-for-lam561-in-combination-with-standard-of-care-in-first-line-therapy-for-newly-diagnosed-glioblastoma-mgmt-methylated-patients-302393021.html

Aaabbbcccddd 04/03/25 21:04

Ha respondido al tema Laminar Pharmaceuticals

"Laminar Pharma, empresa del Parque Científico de Alicante, anuncia datos prometedores sobre la supervivencia libre de progresión en su ensayo clínico con LAM561 para el tratamiento del glioblastoma"https://pca.ua.es/es/noticias/2025/marzo/laminar-pharma-empresa-del-parque-cientifico-de-alicante-anuncia-datos-prometedores-sobre-la-supervivencia-libre-de-progresion-en-su-ensayo-clinico-con-lam561-para-el-tratamiento-del-glioblastoma.html

Aaabbbcccddd 24/02/25 10:52

Ha respondido al tema Laminar Pharmaceuticals

Entrevista fechada a principios de febrero:https://capital-radio-ondemand.flumotion.com/capital-radio/ondemand/outgoing/audio/mp3/low/20250206_BIOTECNOLOGIA.mp3- Se evita hablar de que los resultados (hasta ahora) no hayan sido los anunciados repetidamente en entrevistas / comunicaciones anteriores.- Se sigue siendo optimista sobre el potencial de la molecula.

No hay más resultados